U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07502287) titled 'Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma' on March 25.
Brief Summary: This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates preliminary activity
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Relapsed Neuroblastoma
Refractory Neuroblastoma
High-Risk Neuroblastoma
Ganglioneuroblastoma
Intervention:
BIOLOGICAL: EB-DTNB-NK
Allogeneic, cord blood-d...